BiotechTube

Faricimab + Aflibercept

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Edema

Conditions

Macular Edema, Branch Retinal Vein Occlusion

Trial Timeline

Mar 2, 2021 → Jun 12, 2023

NCT ID
NCT04740905

About Faricimab + Aflibercept

Faricimab + Aflibercept is a phase 3 stage product being developed by Chugai Pharmaceutical for Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT04740905. Target conditions include Macular Edema, Branch Retinal Vein Occlusion.

What happened to similar drugs?

20 of 20 similar drugs in Macular Edema were approved

Approved (20) Terminated (3) Active (0)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved
✅Ozurdex + AfliberceptAbbVieApproved
✅RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04740905Phase 3Completed
NCT04740931Phase 3Completed

Competing Products

20 competing products in Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
25
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26
volociximabAstellas PharmaPhase 1
29